Paul Badawi

“Sight Sciences, we're an ophthalmic medical device company in growth stage. We are focused on two of the major problems in eye care, glaucoma and dry eye disease.”

“We delivered a strong second quarter, with revenue growing 20% year over year, our highest growth rate since 2023, and our second consecutive quarter of double-digit growth.”

“Excited to share the Sight Sciences story with everyone. Our mission at Sight is to develop transformative interventional technologies that procedurally elevate the standard of care, allowing eye care providers to elevate the standard of care and empower patients to keep seeing.”

“We delivered a strong start to 2026 with first quarter results that demonstrated a return to double-digit revenue growth, continued strength in gross margin, and disciplined operating expense and cash management.”

“We ended 2025 with solid execution across our business, highlighted by fourth quarter revenue growth in both segments, strong gross margins, and continued operating expense discipline in cash management.”